ES2153786B1 - Composicion farmaceutica liquida para la administracion oral de principios activos amargos y susceptibles de hidrolisis. - Google Patents

Composicion farmaceutica liquida para la administracion oral de principios activos amargos y susceptibles de hidrolisis.

Info

Publication number
ES2153786B1
ES2153786B1 ES009901281A ES9901281A ES2153786B1 ES 2153786 B1 ES2153786 B1 ES 2153786B1 ES 009901281 A ES009901281 A ES 009901281A ES 9901281 A ES9901281 A ES 9901281A ES 2153786 B1 ES2153786 B1 ES 2153786B1
Authority
ES
Spain
Prior art keywords
pharmaceutical composition
oral administration
liquid pharmaceutical
amarge
principles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES009901281A
Other languages
English (en)
Other versions
ES2153786A1 (es
Inventor
Carreras Manel Roig
Arino Pere Tubau
Rubio Jordi Julve
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Salvat SA
Original Assignee
Laboratorios Salvat SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Salvat SA filed Critical Laboratorios Salvat SA
Priority to ES009901281A priority Critical patent/ES2153786B1/es
Priority to EP00935230A priority patent/EP1190720B1/en
Priority to DE60009290T priority patent/DE60009290D1/de
Priority to ES00935230T priority patent/ES2215665T3/es
Priority to AT00935230T priority patent/ATE262350T1/de
Priority to PCT/ES2000/000206 priority patent/WO2000076549A1/es
Publication of ES2153786A1 publication Critical patent/ES2153786A1/es
Application granted granted Critical
Publication of ES2153786B1 publication Critical patent/ES2153786B1/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"Composición farmacéutica líquida para la administración oral de principios activos amargos y susceptibles de hidrólisis". Por cada 100 ml comprende: 3-15 g de principio activo; 0,01-0,3 g de conservante (ácido sórbico, p-hidroxibenzoato de metilo); la cantidad suficiente para 100 ml de un vehículo oleoso comestible formado por triglicéridos de ácidos de cadena corta o media (caprílico, cáprico); una cantidad adecuada de edulcorante (sacarina sódica, ciclamato sódico, glicirrinato amónico), acompañada opcionalmente de una cantidad adecuada de aromatizante (nuez, leche condensada, coco, plátano); 0,5-2 g de lecitina de soja; 0,1-5 g de un espesante de tipo derivado de celulosa (N- etilcelulosa); y 0,05-1 g de un tensioactivo de tipo polisorbato. Opcionalmente comprende 0,5-5 g de manitol y 1-5 g de bicarbonato sódico. Es útil para administrar principios activos amargos (ciprofloxacino, paracetamol, eritromicina, etc) a niños, ancianos y pacientes poco motivados, resultando estable, fácil deingerir, y de sabor soportable.
ES009901281A 1999-06-10 1999-06-10 Composicion farmaceutica liquida para la administracion oral de principios activos amargos y susceptibles de hidrolisis. Expired - Lifetime ES2153786B1 (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ES009901281A ES2153786B1 (es) 1999-06-10 1999-06-10 Composicion farmaceutica liquida para la administracion oral de principios activos amargos y susceptibles de hidrolisis.
EP00935230A EP1190720B1 (en) 1999-06-10 2000-06-08 Liquid pharmaceutical composition for oral administration of bitter hydrolysis-susceptible active substances
DE60009290T DE60009290D1 (de) 1999-06-10 2000-06-08 Flüssige pharmazeutische zusammensetzung zur oralen verabreichung bitterschmeckender hydrolyseempfindlicher aktivstoffe
ES00935230T ES2215665T3 (es) 1999-06-10 2000-06-08 Composicion farmaceutica liquida para la administracion oral de sustancias activas amargas susceptibles de hidrolisis.
AT00935230T ATE262350T1 (de) 1999-06-10 2000-06-08 Flüssige pharmazeutische zusammensetzung zur oralen verabreichung bitterschmeckender hydrolyseempfindlicher aktivstoffe
PCT/ES2000/000206 WO2000076549A1 (es) 1999-06-10 2000-06-08 Composicion farmaceutica liquida para la administracion oral de principios activos amargos y susceptibles de hidrolisis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009901281A ES2153786B1 (es) 1999-06-10 1999-06-10 Composicion farmaceutica liquida para la administracion oral de principios activos amargos y susceptibles de hidrolisis.

Publications (2)

Publication Number Publication Date
ES2153786A1 ES2153786A1 (es) 2001-03-01
ES2153786B1 true ES2153786B1 (es) 2001-10-16

Family

ID=8308775

Family Applications (2)

Application Number Title Priority Date Filing Date
ES009901281A Expired - Lifetime ES2153786B1 (es) 1999-06-10 1999-06-10 Composicion farmaceutica liquida para la administracion oral de principios activos amargos y susceptibles de hidrolisis.
ES00935230T Expired - Lifetime ES2215665T3 (es) 1999-06-10 2000-06-08 Composicion farmaceutica liquida para la administracion oral de sustancias activas amargas susceptibles de hidrolisis.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES00935230T Expired - Lifetime ES2215665T3 (es) 1999-06-10 2000-06-08 Composicion farmaceutica liquida para la administracion oral de sustancias activas amargas susceptibles de hidrolisis.

Country Status (5)

Country Link
EP (1) EP1190720B1 (es)
AT (1) ATE262350T1 (es)
DE (1) DE60009290D1 (es)
ES (2) ES2153786B1 (es)
WO (1) WO2000076549A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004535370A (ja) 2001-03-05 2004-11-25 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 味をマスクした液体製薬学的組成物
EP1401402B1 (en) * 2001-05-29 2016-09-07 Takeda Pharmaceuticals U.S.A., Inc. Enhancement of oral bioavailability of non-emulsified formulation of cefditoren pivoxil with lecithin
GB2380936B (en) * 2001-10-18 2003-07-09 Reckitt Benckiser Healthcare Improvements in or relating to compositions
WO2008135957A2 (en) 2007-05-07 2008-11-13 Koninklijke Philips Electronics N.V. A method for cleaning dental plaque from teeth using an adherent peelable gel
GB0720967D0 (en) * 2007-10-25 2007-12-05 Protophama Ltd Anti-material pharmaceutical composition
DE102010015143A1 (de) * 2010-04-16 2011-10-20 Cts Chemical Industries Ltd. Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon
ES2929945T3 (es) * 2013-11-13 2022-12-05 National Defense Education And Res Foundation Nueva composición de un compuesto de acetaminofeno sin efectos secundarios sobre el hígado
JP6858729B2 (ja) * 2018-05-25 2021-04-14 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
US12605388B2 (en) 2024-09-25 2026-04-21 Azurity Pharmaceuticals Ireland Limited Lamotrigine salts, co-crystals, and compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004893A1 (en) * 1990-09-13 1992-04-02 Smithkline Beecham Corporation Non-aqueous liquid oral suspensions
JP3419957B2 (ja) * 1995-06-06 2003-06-23 花王株式会社 味覚改質剤
ES2105970B1 (es) * 1995-08-02 1998-07-01 S A L V A T Lab Sa Composicion farmaceutica oral de ciprofloxacino, no acuosa, estable y con caracteristicas organolepticas mejoradas.

Also Published As

Publication number Publication date
ATE262350T1 (de) 2004-04-15
ES2215665T3 (es) 2004-10-16
ES2153786A1 (es) 2001-03-01
EP1190720A1 (en) 2002-03-27
WO2000076549A1 (es) 2000-12-21
DE60009290D1 (de) 2004-04-29
EP1190720B1 (en) 2004-03-24

Similar Documents

Publication Publication Date Title
US5369131A (en) Oral, cutaneous and intravaginal pharmaceutical compositions in the form of foam
US6806256B2 (en) Taste masked liquid pharmaceutical compositions
FR2789329B1 (fr) Composition cosmetique et/ou dermatologique constituee par une emulsion du type huile-dans-l'eau formee de vesicules lipidiques dispersees dans une phase aqueuse contenant au moins un actif acide hydrophile
ES2791775B2 (es) Formulaciones de epinefrina intranasal y metodos para el tratamiento de enfermedades
ATE117547T1 (de) Orale lipidarzneiform.
BR0211794A (pt) Composição farmacêutica e método para mascarar o sabor de pelo menos um composto farmaceuticamente ativo de sabor desagradável
PT94504B (pt) Processo para a preparacao de composicoes farmaceuticas aquosas em suspensao para ingredientes activos substancialmente insoluveis em agua
JP4051717B2 (ja) ビオチン含有内服液剤
CA2466036C (en) Taste masking spill-resistant formulation
WO2002064148A3 (en) Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
DE60009290D1 (de) Flüssige pharmazeutische zusammensetzung zur oralen verabreichung bitterschmeckender hydrolyseempfindlicher aktivstoffe
CA2215327A1 (en) Formulations for lipophilic compounds
EP0548238A1 (en) Non-aqueous liquid oral suspensions
AU2002356831A1 (en) Taste masking spill-resistant formulation
BE900749A (fr) Medicament microencapsule dans une matrice sucree.
EP0315332B1 (en) Antitussive liquid compositions containing phenol
JP4373649B2 (ja) 経口用液剤
ES2318277T3 (es) Composicion farmaceutica que compresnde acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico.
Thosar Intra oral sprays-An overview.
EP0927031B1 (en) Pharmaceutical preparation containing nimesulide for oral administration
ES2338972B1 (es) Composicion farmaceutica liquida de ibuprofeno y codeina para su administracion por via oral, su procedimiento de preparacion y utilizacionde la misma.
US20060100271A1 (en) Stabilized aqueous ranitidine compositions
Mrestani et al. Improvement of lipophilicity and membrane transport of cefuroxime using in vitro models
JPH09286723A (ja) 改善された経口液剤
JPH09124593A5 (es)

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20010301

Kind code of ref document: A1

Effective date: 20010301

FA2A Application withdrawn

Effective date: 20031120